1. Home
  2. TENX vs MCVT Comparison

TENX vs MCVT Comparison

Compare TENX & MCVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TENX
  • MCVT
  • Stock Information
  • Founded
  • TENX 1967
  • MCVT 2007
  • Country
  • TENX United States
  • MCVT United States
  • Employees
  • TENX N/A
  • MCVT N/A
  • Industry
  • TENX Biotechnology: Pharmaceutical Preparations
  • MCVT Finance Companies
  • Sector
  • TENX Health Care
  • MCVT Finance
  • Exchange
  • TENX Nasdaq
  • MCVT Nasdaq
  • Market Cap
  • TENX 19.5M
  • MCVT 11.6M
  • IPO Year
  • TENX N/A
  • MCVT N/A
  • Fundamental
  • Price
  • TENX $5.61
  • MCVT $1.99
  • Analyst Decision
  • TENX Strong Buy
  • MCVT
  • Analyst Count
  • TENX 4
  • MCVT 0
  • Target Price
  • TENX $20.67
  • MCVT N/A
  • AVG Volume (30 Days)
  • TENX 67.9K
  • MCVT 5.7K
  • Earning Date
  • TENX 11-13-2024
  • MCVT 11-12-2024
  • Dividend Yield
  • TENX N/A
  • MCVT N/A
  • EPS Growth
  • TENX N/A
  • MCVT N/A
  • EPS
  • TENX N/A
  • MCVT 0.05
  • Revenue
  • TENX N/A
  • MCVT $3,234,265.00
  • Revenue This Year
  • TENX N/A
  • MCVT N/A
  • Revenue Next Year
  • TENX N/A
  • MCVT N/A
  • P/E Ratio
  • TENX N/A
  • MCVT $40.51
  • Revenue Growth
  • TENX N/A
  • MCVT N/A
  • 52 Week Low
  • TENX $2.77
  • MCVT $1.75
  • 52 Week High
  • TENX $27.36
  • MCVT $3.88
  • Technical
  • Relative Strength Index (RSI)
  • TENX 54.30
  • MCVT 51.73
  • Support Level
  • TENX $5.70
  • MCVT $1.91
  • Resistance Level
  • TENX $6.01
  • MCVT $2.05
  • Average True Range (ATR)
  • TENX 0.47
  • MCVT 0.06
  • MACD
  • TENX -0.08
  • MCVT 0.01
  • Stochastic Oscillator
  • TENX 12.15
  • MCVT 52.38

About TENX Tenax Therapeutics Inc.

Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.

About MCVT Mill City Ventures III Ltd.

Mill City Ventures III Ltd is a non-bank lender and specialty finance company. The company is engaged in the business of providing short-term specialty finance solutions primarily to private businesses, micro-and small-cap public companies, and high-net-worth individuals. The principal specialty finance solutions that they provide are high-interest short-term lending arrangements. Typically, these lending arrangements involve obtaining collateral as security for the borrower's repayment of funds, or personal guarantees from the principals or affiliates of the borrower.

Share on Social Networks: